Data from trials like Niagara suggests a powerful new paradigm for assessing treatment success. Combining urine tumor DNA (uTDNA) for local disease and circulating tumor DNA (ctDNA) for systemic relapse offers a more dynamic view than traditional pathology and is poised to become the superior surrogate endpoint in bladder cancer trials.

A key conceptual shift is viewing ctDNA not as a statistical risk marker, but as direct detection of molecular residual disease (MRD). This framing, similar to how a CT scan identifies metastases, explains its high positive predictive value and justifies its use in making critical treatment decisions.

Experts predict that emerging cell-free DNA (ctDNA) tests for lymphoma will shift treatment from fixed durations to a response-adapted approach. Monitoring minimal residual disease via ctDNA will allow clinicians to tailor the length of therapy based on the quality of response.

Minimal Residual Disease (MRD) negativity is now recognized by regulators as a surrogate endpoint in oncology. Because it is considered 'reasonably likely to predict progression-free survival,' this shift allows drug developers to use MRD data to support accelerated approval pathways, expediting the availability of new therapies.

In the Serena 6 trial, patients whose circulating tumor DNA (ctDNA) was cleared after switching to camazestrant had a significantly improved overall survival (HR 0.4). This exploratory finding suggests ctDNA monitoring can be a potent early indicator of long-term treatment success, potentially reshaping how therapeutic efficacy is measured long before imaging can.

Circulating tumor DNA (ctDNA) testing is described as unequivocally the most prognostic tool available for colorectal cancer. Patients who remain serially negative have a minimal recurrence risk, while a positive result almost universally predicts a future clinical recurrence by 6-8 months.

The ideal use for cell-free DNA tests is tracking 'minimal residual disease' in patients already treated for cancer. In this high-risk group, the base rate of recurrence is much higher, making a positive test result far more reliable and actionable for early intervention.

The INTERCEPT study found only 2% of ctDNA-positive colorectal cancer patients clear the marker without intervention. This stable, high-risk baseline allows small trials to use ctDNA clearance as a rapid endpoint, potentially accelerating the development of new adjuvant therapies.

Emerging data from major trials shows that ctDNA clearance during neoadjuvant therapy and negative post-surgical MRD status are strong predictors of improved survival. MRD positivity, in contrast, is associated with worse biology and rapid progression.